Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Peg-IFN-Alpha-2A + Ribavirin 48 vs 72 Weeks in HCV/HIV Co-infection
NCT02761629Phase 4Completed
- Sponsor
- Roche
- Start
- Apr 2005
- Primary completion
- May 2008
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of peginterferon alfa-2a and ribavirin in chronic hepatitis C (CHC) (2 arms), sponsored by Roche. Primary endpoint: Sustained Virologic Response. Started Apr 2005; status: completed.
02
Drugs
peginterferon alfa-2aribavirin
03
Conditions
chronic hepatitis C (CHC)
Beyond the preview
Go deeper on NCT02761629.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02761629.